← All trials
NCT04766177
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2021
- Primary completion
- Dec 1, 2030
- Completion date
- Dec 1, 2030
- First posted
- Feb 23, 2021
- Last posted
- Feb 23, 2021
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tanta UniversityLead sponsor
- Tanta UniversitySponsor investigator
- Kafrelsheikh UniversityOverall official - principal investigator
- Kafrelsheikh UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.